Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience

Martina Baur1,2, Matthias Preusser3,4, Maria Piribauer3, Katarzyna Elandt3, Marco Hassler3, Marcus Hudec5, Christian Dittrich1,2, Christine Marosi3

1 Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIEnna/CEADDP), Vienna, Austria
2 Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna)-Ludwig Boltzmann Cluster Translational Oncology, Kaiser Franz Josef-Spital, Vienna, Austria
3 Department of Internal Medicine I, Medical University Vienna, Vienna, Austria
4 Institute of Neurology, Medical University Vienna, Vienna, Austria
5 Department of Scientific Computing, University of Vienna, Vienna, Austria

Received 18 March 2010
Accepted 6 April 2010

Correspondence to: Martina Baur, M.D., Assoc. Prof. of Medicine, Ludwig Boltzmann-Institute for Applied Cancer Research (LBI-ACR VIEnna)-Ludwig Boltzmann Cluster Translational Oncology, 3rd Medical Department-Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria. Phone: +43 1 60 1 91 2308; Fax: +43 1 60 1 91 2309; E-mail: martina.baur@gmx.net

Disclosure: No potential conflicts of interest were disclosed.

Background. The aim of this retrospective study was to analyse the MGMT (06-methylguanine-DNA methyltransferase) promoter methylation status in long-term surviving (≥ 3 years) patients with glioblastoma multiforme (GBM).

Methods. The methylation status of the MGMT promoter was determined by bisulfite modification of the DNA and subsequent methylation-specific polymerase-chain-reaction (MSP). DNA was extracted from routinely formalin-fixed and paraffin-embedded tumour tissue samples.

Results. MSP yielded interpretable results in only 14 of 33 (42%) long-term surviving patients with GBM. A methylated band was seen in 3 of 14, methylated as well as unmethylated bands in 8 of 14 and an only unmethylated band in 3 of 14 patients, thus, yielding MGMT promoter methylation in 11 of 14 patients. The two groups of patients with methylated and unmethylated MGMT promoter status were too small to draw any firm statistical conclusions.

Conclusions. Long-term surviving patients with GBM have very frequently intratumoural MGMT promoter methylation. This phenomenon discriminates long-term survivors from a non-selected group of patients with GBM. The standardization of the MSP for the determination of the MGMT promoter methylation status seems to be necessary in order to make this methodology a more reliable one.

Key words: glioblastoma multiforme (GBM); high grade glioma; MGMT promoter methylation; hypermethylation; long-term survival

Introduction

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. It represents the most frequently encountered type of glial tumours and can also occur in children.1,2 Median survival is generally only slightly longer than one year based on multimodal approaches consisting of maximal feasible resection, radiotherapy and chemotherapy. A substantial step forward in the treatment of GBM was reached by the randomized phase III trial by Stupp et al., demonstrating a significantly longer survival in patients treated with temozolomide in addition to radiotherapy followed by adjuvant temozolomide with a median survival of 15 months and a five-year survival rate of 9.8%.3

Distinct from unselected GBM patients, who survive about one year, there is a small subgroup
of 1%-5% of patients with GBM that survive at least 3 years after the diagnosis of GBM.\textsuperscript{4,12} They are designated as long-term glioblastoma survivors. This period of 36 months survival was also adopted in our study as the lower limit for long-term surviving GBM patients; yet, there is no generally accepted definition. All histologic diagnoses of the putative long-term surviving GBM patients have to be reviewed because in about one half of the cases the histologic diagnosis of GBM is reclassified to represent a less malignant tumour, namely oligodendroglioma, malignant mixed oligodendroglioma-astrocytoma or anaplastic astrocytoma.\textsuperscript{6-10,13} Although the histologic aspect of the tumours from long-term survivors does not differ from that of classical survivors, it is postulated that the long-term surviving patients are a subgroup of GBM patients with a different biological behaviour, a different therapeutic responsiveness and a distinct genetic characterization.

Clinical parameters such as young age, high Karnofsky performance status and the extent of radicality of surgery are associated with a better prognosis despite the histology of a GBM.\textsuperscript{4,6-8,10,14,15} Scott et al. found additional factors as the neurologic function and the dose of radiotherapy applied in their recursive partitioning analysis to be important prognostic variables.\textsuperscript{16} The period of symptoms before the diagnosis in long-term GBM survivors in contrast to average GBM patients is significantly longer.\textsuperscript{10} A significantly lower Ki-67-labeling index compared to controls has been described in tumours from long-term survivors.\textsuperscript{10} Such patients exhibit fewer genetic aberrations than typical GBM patients.\textsuperscript{7} Like in oligodendroglioma patients the loss of 19q is exclusive to the long-term survivors.\textsuperscript{1} Usually 6q loss, 10q loss and 19 q gain are associated with the short-term survival\textsuperscript{7} whereas mdm2 overexpression is less likely exhibited by the long-term GBM survivors.\textsuperscript{5} Molecular parameters, which can determine the step of tumour malignancy,\textsuperscript{17} are also important in GBM patients.\textsuperscript{5} The overexpression of the protein p53 and the nuclear p53 expression are significantly more frequently found in long-term surviving patients.\textsuperscript{5} A better molecular characterization of long-term GBM patients is achieved by examining of multiple markers suggesting that differing patterns of genetic lesions may discriminate between the long and the short-term survival of GBM patients.\textsuperscript{7}

It has become clear that cancers in general arise from both genetic and epigenetic changes. Epigenetic changes, such as hypermethylation, may inactivate genes without changing the base sequence. Analysing a different promoter methylation status of key regulator genes implicated in apoptosis and inflammation hypermethylation of TMS1/ASC was significantly more frequent in long-term surviving GBM patients and DAPK promoter hypermethylation was only found in the long-term subset compared to unselected GBM patients.\textsuperscript{4} Martinez et al.\textsuperscript{18} found a significantly higher methylation rate of MGMT in long-term GBM patients compared to unselected GBM patients. The MGMT gene is located on chromosome 10q26. Methylation of the gene promoter is associated with the loss of MGMT expression which results in diminished DNA-repair activity. Tumour cells lacking MGMT are prone to cell death induced by alkylating substances such as temozolomide. In this process the alkyl-group is transferred to the active site of the MGMT protein that thereby becomes irreversibly inactivated and subsequently degraded, requiring resynthesis. Although O\textsuperscript{6}-methylguanine accounts for less than 10% of the lesions induced by alkylating agents, it plays a major role as a trigger for cytotoxicity and apoptosis. If left unrepaired, e.g. due to epigenetic silencing of the MGMT gene or depletion the MGMT protein by saturation of the process, O\textsuperscript{6}-methylguanine persists in the DNA.\textsuperscript{19} Recently, Hegi et al.\textsuperscript{20} Glas et al.\textsuperscript{21} and Sonoda et al.\textsuperscript{22} described promoter methylation of MGMT as an independent favourable prognostic factor. Patients with GBM containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.\textsuperscript{20}

To further characterize long-term glioblastoma patients genetically we investigate retrospectively the MGMT promoter methylation status by the bisulfite modification of the DNA and subsequent methylation-specific polymerase-chain-reaction (MSP) in formalin-fixed and paraffin-embedded tumour tissue samples of 33 long-term survivors with GBM from a single centre.

**Patients and methods**

**Patient recruitment**

Primary and secondary GBM patients surviving longer than 36 months after the diagnosis were retrospectively identified in a single centre, the Department of Internal Medicine I, University of Vienna, Vienna, Austria starting from the year 1995...
up to 2003. The histologic diagnosis of GBM according to the World Health Organization (WHO) classification of the brain tumors was confirmed by the pathology review by M.P. All patients have been treated with alkylating agents. The clinical data were evaluated by checking patients’ records, the presence and the extent of oedema by reviewing the radiologic films. A cognitive impairment was assessed by analysing the dialogues between the treating physicians and the patients; additionally, the functional capacities regarding ADL (activities of daily living) and IADL (instrumental activities of daily living) documented as reported by the relatives were scored. This study has been approved by the local ethics committee and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. The informed consent for samples and the data analysis from each patient had been obtained.

MGMT promoter methylation analysis

A MGMT promoter methylation status was analysed using methylation-specific PCR (MSP) as described by Hegi et al. In brief, genomic DNA was isolated from paraffin sections of GBM tissue using Ex-Wax DNA Extraction (Chemicon, Temecula, California, USA). The DNA was subjected to bisulfite treatment at 56°C for 16-20h. Then the DNA was purified using Wizard DNA Clean-Up System A7280 (Promega, Madison, Wisconsin, USA). MSP was performed in a two-step “nested” approach using previously defined primer sets. The PCR products were separated on two percent agarose gels. A glioblastoma case with a known methylated MGMT promoter was used as the positive control and water was used as the negative control for MSP analysis.

MIB-1 proliferation index immunohistochemistry

Tumour sections (3-5 micrometers thick) were immunostained with a monoclonal mouse anti-Ki-67 antibody (clone MIB-1, Dako, Glostrup, Denmark) at a dilution of 1:50 for 25 minutes. For the determination of the MIB-1 proliferation index, the fraction of labelled nuclei per 500 tumour cell nuclei was manually counted using an eye grid and was expressed as percentage.

Statistical analysis

Time to progression reached from the date of the first neurosurgical procedure or diagnosis of glioblastoma to the time of the first objective evidence of tumour progression or the time of censoring. Survival time was defined as the time lapse from the initial surgery or diagnosis to the patient’s death or the time of censoring. Time to progression and survival were estimated using the Kaplan-Meier method. The influence on time to progression and overall survival by sex, age, presence of primary or secondary glioblastoma, side and region of the brain of the primary tumour, presence of cognitive impairment, presence of oedema and Karnofsky performance status was calculated by the log-rank test. For the analysis of the influence of the age of the formalin-fixed or paraffin embedded tumour tissue on the feasibility of determination of the MGMT promoter methylation status a χ²-test was used. All statistical analyses were performed using the SPSS software 15.0.

Results

In this retrospective analysis 35 long-term surviving patients with GBM were identified from one centre. 33 of them were confirmed GBM patients after the histologic review indicating a percentage of 6% of revised histologies. The two diagnoses of the reclassified histologies were anaplastic oligodendroglioma and anaplastic astrocytoma. As 40 patients per year with primary GBM are treated in the institution this results in about four patients per year becoming long-term surviving GBM patients. This corresponds to an estimated percentage of 10% of long-term survivors in the institution. The median follow-up was 54.2 ±SD 26.1 months. The patient’s characteristics are shown in Table 1.

Karnofsky performance score

The postoperative Karnofsky performance score of the long-term surviving patients was at least 80%. At the time of writing two women and three men were professionally still active, the two women as computer clerks with full time employment, one of the men as a teacher for mathematics in a vocational school, one as a farmer and the third as a pizza cook.
Local relapses

20 of 33 (61%) patients suffered a local relapse, eleven of them after gross total resection of the primary tumour.

Median time to progression

The median time to progression (TTP) was 39 months [95% CI: 0; 105.6] (Figure 1). Patients with a biopsy at initial diagnosis had a median TTP of 5.3 months [95% CI: 0; 17.8 months] (n=4), patients with a subtotal resection had a TTP of 39.3 months [95% CI: 0-92 months] (n=10) and patients with a total resection one of 66.9 months [95% CI: 0; 145.3 months] (n=19), respectively. The clinical parameters age, sex, oedema, side and region of the brain of the primary tumour and Karnofsky performance status did not impact on the TTP. Patients with the unmethylated MGMT promoter had a time to progression of 7, 39 and 79+ months whereas patients with methylated MGMT promoter had a TTP of 5 to 56+ months.

Survival

At the time of evaluation, 15 patients were alive, seven of them without tumour recurrence for up to 151+ months. The median survival was 83 months [95% CI: 43.8-122.3] (Figure 2). Patients with a subtotal resection survived 47.2 months [95% CI: 28.8-65.6 months] and patients with a total resection 83.0

TABLE 1. Patient characteristics

|                          | N (%)   |
|--------------------------|---------|
| Number of patients       | 33      |
| Age (years) median (range)| 38 [22-66] |
| Sex                      |         |
| Male                     | 22 (66.7) |
| Female                   | 11 (33.3) |
| Performance status acc. to Karnofsky (%) | |
| 60                       | 1 (3.1) |
| 70                       | 3 (9.1) |
| 80                       | 11 (33.3) |
| 90                       | 14 (42.4) |
| 100                      | 4 (12.1) |
| Oedema                   |         |
| ≤ 1 cm                   | 11 (33.3) |
| > 1 cm                   | 19 (57.6) |
| n.e.                     | 3 (9.1) |
| History of glioblastoma  |         |
| Primary glioblastoma     | 31 (93.9) |
| Secondary glioblastoma   | 2 (6.1) |
| Localisation of the tumour|        |
| Frontal                  | 12 (36.4) |
| Parietal                 | 4 (12.1) |
| Trigonal                 | 2 (6.1) |
| Temporal                 | 8 (24.2) |
| Occipital                | 1 (3.0) |
| Frontoparietal           | 1 (3.0) |
| Insula                   | 1 (3.0) |
| Parietooccipital         | 2 (6.1) |
| Thalamus                 | 2 (6.1) |
| Side of tumour localisation|      |
| Right                    | 10 (30.3) |
| Left                     | 22 (66.7) |
| Bilateral                | 1 (3)    |
| Extent of resection      |         |
| Biopsy                   | 4 (12.1) |
| Subtotal                 | 10 (30.3) |
| Total                    | 19 (57.6) |
| Cognitive impairment     |         |
| Yes                      | 11 (33.3) |
| No                       | 22 (66.7) |
| Stroke                   |         |
| Yes                      | 2 (6.1) |
| No                       | 31 (93.9) |
| Initial chemotherapy     |         |
| Temozolomide             | 6/33 (18.2%) |
| CCNU                     | 15/33 (45.5%) |
| Fotemustine/Dacarbazine  | 12/33 (36.4%) |

N = numbers, n.e. = not evaluable
months [95% CI: 43.2; 122.9 months], respectively. The clinical parameters age, sex, oedema, side and region of the brain of the primary tumour and Karnofsky performance status did not impact on the survival. Of note, nine of the patients with a local relapse survived longer than five years. Patients with the unmethylated MGMT promoter had a survival of 43, 79+ and 97+ months, respectively. Patients with the methylated MGMT promoter had a median survival of 48 ± SD 0.97 months.

**MIB-1 scoring**

In seven patients the immunohistochemical staining of MIB-1 was determined. The mean MIB-1 score was 29.1%, the median 30.3% (range 12.1 - 49%).

**MGMT promoter methylation status (Table 2)**

Only in 14 of 33 (42%) patients the determination of the MGMT promoter methylation status by MSP yielded interpretable results. There was no linear correlation of the success rate to the age of the paraffin block (p=0.5). Of 14 patients with interpretable MSP results, three of 14 patients had a methylated MGMT promoter, three of 14 patients an unmethylated MGMT promoter and 8 of 14 patients partly a methylated and partly an unmethylated MGMT promoter. Thus, the MGMT promoter methylation was found in 11 of the 14 patients. These two groups of patients with the methylated and the unmethylated MGMT promoter status, respectively, were too small to draw reliable conclusions based on statistical testing.

## Discussion

Reports on the MGMT promoter methylation status in long-term surviving patients with glioblastoma multiforme are scarce. 78.5% of long-term survivors presented with MGMT promoter hypermethylation. This is in the same range as reported by Martinez et al., Sonoda et al. and Krex et al.18,22,23 This high proportion of patients with the MGMT promoter methylation is in clear contrast the 44% (range 25- 68%) determined from 13 different studies of unselected patients with GBM.18,20,24,34 However, the high rate of methylated tumours in the long-term surviving patients let suggest that MGMT promoter methylation is of paramount importance for response to the actual standard therapy with alkylating agents in GBM.3 The proof of this principle is eagerly awaited in form of the results of the prospective Intergroup trial RTOG0525/EORTC26052 which will not yet be presented at ASCO 2010 testing dose-intense temozolomide in comparison to standard-dose temozolomide dependent on the MGMT promoter methylation status in GBM patients.

Although 33 patients were initially included in our analysis of long-term surviving patients with GBM, the paraffin embedded tissue blocks of only 14 out of 33 (42%) patients were suitable for the MGMT hypermethylation test by MSP. Because of the small number of patients it was impossible to determine whether the MGMT methylation status was of prognostic impact in our patient cohort. The MGMT promoter methylation status as a prognostic factor in long-term surviving GBM patients should be further evaluated in prospective studies.

The statistical analysis did not show a significant difference between older paraffin embedded tissue in contrast to younger patient samples.
DNA. Especially in tumour biopsies tumour cells of the tumour specimens did not contain enough malignant cells. Herrlinger recovered due to extensive necrosis and scarcity of a very small amount of partially degraded DNA is fresh frozen tissue are discussed. Frequently only tumour tissue of patients with GBM compared to success rate of MSP testing in paraffin-embedded tumour, including infiltrating lymphocytes, are not easily found. Hau et al. recommended a good quality paraffin embedded tissue that is not overfixed. The accumulation of normal cells in the tumour, may complicate accurate assessment of MGMT. The best results with methylation-specific PCR are obtained with cryopreserved tumour specimens, thus avoiding the fixation-related deterioration of the quality of DNA. 8 of 14 our patients exhibited both the methylated and the unmethylated MGMT promoter. Our observation is in the same range as reports by Martinez et al., Blanc et al., Criniere et al., Cankovic et al. and Gonzalez-Gomez et al. who found that the majority of the methylated tumours also exhibited an unmethylated band, which may arise from either normal cells within the tumour sample or from a tumour cell side population. Experience shows that MGMT promoter methylation testing may be technically challenging. Several methods including multiplex ligation probe amplification MLPA, real time quantitative polymerase chain reaction (quantitative rt-PCR), have been proposed as potential alternatives to conventional MSP. These methods need to be critically evaluated in future studies and reliable cut-off values for the prognostication and the prediction have to be prospectively validated.

Two of 33 (6%) patients of our study suffered from secondary GBM. This percentage was markedly lower than the incidence of 20% reported by Steinbach et al. In these two patients with secondary GBM in our study the MGMT promoter methylation determination was not feasible due to technical reasons.

The determination of the proliferative activity in form of MIB-1 evolved a low median score of 30.3 (range 12.1-49). This observation correlated well with the results reported by Ho et al., demonstrating a cut-off value of ≥ 35 being related to worse outcome in unselected GBM patients. However, due to sampling differences, there has no clear prognostic impact of Ki-67 on the survival of GBM patients been detected.

In addition to the MGMT methylation status, we compared clinical parameters of our long-term GBM patients like age, Karnofsky-performance score, ratio male/female, localisation of the primary tumour, extent of surgery, laterality of the primary tumour, incidence of cognitive impairment and of ischemic events, incidence of relapses, median survival, to those of other reports of long-term survivors with GBM. Most authors included patients surviving ≥ 3 years, Vertosick et al. those > 4 years, McLendon et al., Steinbach et al. and Salvati et al. patients surviving ≥ 5 years and Morita et al. those ≥ 7 years.

The median age at diagnosis of the patients of this series was 38 years, which is only slightly younger than the median of 41 years (range 37-51 years) observed in 10 different studies and 12 years younger than the average age at diagnosis of unselected GBM patients (median 53 years ± 0.55 years).

One of the most important prognostic factors in cancer patients, the Karnofsky performance score at the beginning of radiochemotherapy in our 33 patients reached median 90%. This equals the median of 90% (range 80-90%) observed in nine other studies of long-term surviving GBM patients and is clearly higher than the median of 76.1% of unselected GBM. The sex ratio male:female in our patient cohort was 67:33, quite similar to other studies. There was no predilection in laterality or in localization in a given cerebral lobe, as in the other series of long-term surviving GBM patients.

The radiological parameter “extent of oedema > 1 cm” at diagnosis of GBM was present in 58% of our patients and did not impact on time to progression or survival in this series. In other studies of long-term surviving patients with GBM oedema was not investigated as a prognostic factor. However, in average patients with GBM, oedema larger than 1 cm has been reported to influence the survival, negatively.

Of note, a gross total resection was achieved in 58% of the patients of this series. This has been reported accordingly in the series by Scott et al. with 40%, Salvati et al. with 46% and Hottinger et al. with 48% but not by McLendon et al. with 27%.
Obtaining a total gross resection appears to be of paramount importance for achieving a long-term survival in GBM patients. A considerably lower percentage of gross total resections of about 40% were recorded in studies of unselected patients. However, in this series four patients (12%) underwent only a biopsy of the primary tumour. In three of these four patients the MGMT status was not evaluable and in the remaining patient the MGMT promoter was unmethylated. This raises hope that even patients without tumour debulking and with unmethylated MGMT promoter status can eventually achieve a long-term survival.

61% of our patients relapsed locally. This was in line with three other reports of long-term surviving GBM patients specifying a percentage ranging from 45-73%. Of note, we did not observe distant relapses in the cohort of long-term surviving patients.

In 33% of our patients a cognitive impairment was recorded. A similar rate of 28% has been reported by Hottinger et al. Two of 33 (6%) of our patients suffered from an ischemic event, this was nearly identical to the 10% observed by Steinbach et al. but clearly lower than the 23% found by Hottinger et al. Further trials will have to evaluate the incidence of ischemic events in long-term surviving patients with GBM, to identify risk factors and establish preventive strategies.

In summary, this series of patients achieving a long-term survival after the diagnosis of GBM illustrates the validity of the prognostic factors defined in the nomogram on the basis of comparative genomic hybridization distinguishing long-term survivors from typical survivors of glioblastoma multiforme. The definitive role of MGMT promoter methylation in directing tailored chemotherapy in GBM patients will be elucidated in the large randomized international intergroup trial RTOG0525/EORTC26052 stratifying GBM patients by MGMT methylation status and randomizing for standard temozolomide in contrast to dose-dense temozolomide therapy. MGMT promoter methylation testing represents a substantial step forward in the treatment of patients with glioblastoma multiforme and enables us to better understand the mode of action of alkylating therapies and the course of the disease. Further, new treatment options exploiting the MGMT promoter methylation mechanism may add to the improvements achieved in this disease.

Acknowledgment

We would like to acknowledge the cooperation with Johannes Hainfellner, M.D., Institute of Neurology, Medical University of Vienna, Vienna, Austria in performing this study.

References

1. Velinar T, Smrdel U, Popovic M, Bunc G. Genetic markers in oligodendrogial tumours. Radiol Oncol 2010; 44: 13-18.
2. Kachanov DY, Dobrenkov KV, Shamarskaya TV, Abdulbaev RT, Inushkina EV, Savkova RF, et al. Solid tumors in young children in Moscow Region of Russian Federation. Radiol Oncol 2008; 42: 39-44.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
4. Martinez R, Schackert G, Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. J Neurooncol 2007; 82: 133-9.
5. Burton EC, Lamborn KR, Forsyth P, Scott J, O’Campo J, Uyehara-Lock J, et al. aberrant p53,m sm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002; 8: 180-7.
6. Steinbach JP, Blacher HP, Herrlinger U, Wick W, Näaple T, Meyermann R, et al. Surviving glioblastoma for more than 5 years: The patient’s perspective. Neurology 2006; 66: 239-42.
7. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 2002; 62: 6205-10.
8. McLendon RE and Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 2003; 98: 1900-1.
9. Senger D, Cairncross JG, Forsyth PAU. Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype? Cancer J 2003; 9: 214-21.
10. Scott JN, Rewcastle NB, Brasher PMA, Fulton D, MacKinnon JA, Hamilton M, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999; 46: 183-8.
11. Vertosick FT, Sellek RG. Long-term survival after the diagnosis of malignant glioma. A series of 22 patients surviving more than 4 years after diagnosis. Surg Neurol 1992; 38: 359-63.
12. Salusti M, Cervoni L, Artico M, Caruso R, Gagliardi FM. Long-term survival in patients with supratentorial glioblastoma. J Neurooncol 1998; 36: 61-4.
13. Moretz M, Rosenblum MK, Bilsky MH, Fraser RAR, Rosenfeld MR. Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neurooncol 1996; 27: 259-66.
14. Nieder C, Grosu AL, Astner S, Molls M. Treatment of unresectable glioblastoma multiforme. Anticancer Res 2005; 25: 4605-10.
15. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008; 9: 29-38.
16. Scott CB, Scarantino C, Urtasun R, Movas B, Jones CJ, Simpson JR, et al. Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998; 40: 51-5.
17. Irani A. Antigen expression on recurrent meningioma cells. *Radiol Oncol* 2010; 44: 107-12.

18. Martinez R, Schackert G, Yaya-Tor R, Rojas-Marcos I, Herman JG, Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. *J Neurooncol* 2007; 83: 91-3.

19. Hau P, Stupp R, Hegi ME. MGMT methylation status: the advent of stratified therapy in glioblastoma? *Dis Markers* 2007; 23: 97-104.

20. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *New Engl J Med* 2005; 352: 997-1003.

21. Glas M, Hapgood C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. *J Clin Oncol* 2009; 27: 1257-61.

22. Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. *Acta Neurochir (Wien)* 2009; 151: 1349-58.

23. Kred D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. *Brain* 2007; 130: 2596-606.

24. Balana C, Ramirez J, Taron M, Roussos Y, Ariza A, Ballester R, et al. O6-methylguanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-choroethyl)-1-nitrosourea but not to temozolomide plus cisplatin in glioblastoma multiforme. *Clin Cancer Res* 2003; 9: 1461-8.

25. Kamiyori T, Tada K, Shiraishi S, Shinohjima N, Kochi M, Ushio Y. Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. *Neurosurgery* 2004; 54: 349-57.

26. Blanc JL, Wager M, Guilhot J, Kusy S, Bataire B, Chantereau T, et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. *J Neurooncol* 2004; 68: 275-83.

27. Weaver KD, Grossman SA, Herman JG. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. *Cancer Invest* 2006; 24: 35-40.

28. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. *N Engl J Med* 2000; 343: 1350-4.

29. Brandes AA, Tosoni A, Cavoli G, Bertorello R, Gioia V, Franceschi E, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). *Br J Cancer* 2006; 95: 1153-60.

30. Hassler M, Seidl S, Fazeny-Doerner B, Preusser M, Hainfellner J, Rössler K, et al. Diversity of cytogenetic and pathohistologic profiles in glioblastoma. *Cancer Genet Cytogenet* 2006; 166: 46-55.

31. Criniere E, Kaloji G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, et al. MGMT prognostic impact on glioblastoma is dependent on thera-peutic modalities. *J Neurooncol* 2007; 83: 173-9.

32. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. *Clin Cancer Res* 2004; 10: 1871-4.

33. Herrerling U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. *J Clin Oncol* 2006; 24: 4412-7.

34. Cankovic M, Mikkelson T, Rosenblum ML, Zarbo RJ. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. *Lab Invest* 2007; 87: 392-7.

35. Alldape KD, Jones G, Wang M, Hegi M, Janzer RC, Stupp R, et al. MGMT methylation testing in RT0525: A phase III trial of newly diagnosed glioblastoma [abstract]. *J Clin Oncol* 2009; 27(Suppl), 155. No. 2051.

36. Dehdashi AR, Hegi ME, Regli L, Pica A, Stupp R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. *Neurosurg Focus* 2006; 20: 1-6.

37. Gonzalez-Gomez P, Bello MJ, Arjona D, Lomas J, Alonso ME, De Campos JM, et al. Promoter hypermethylation of multiple genes in astrocytic gliomas. *Int J Oncol* 2005; 22: 601-9.

38. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? *Nat Rev Neurol* 2010; 6: 39-51.

39. Preusser M, Elezi L, Hainfellner JA. Poor reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. *Clin Neuropathol* 2008; 27: 388-90.

40. Ho DM, Hsu CY, Ting IE, Chiang H. MiB-1 and DNA Topoisomerase IIα could be helpful for predicting long-term survival of patients with glioblastoma. *Am J Clin Pathol* 2003; 119: 715-22.

41. Deb P, Sharma MC, Mahapatra AK, Agarwal D, Sarkar C. Glioblastoma multiforme with long-term survival. *Neural India* 2006; 53: 329-32.

42. Hottinger AF, Youn H, DeAngelis LM, Abrey LE. Neurological outcome of long-term glioblastoma survivors. *J Neurooncol* 2009; 95: 301-5.

43. Gajovic Horvat A, Kovac V, Strojan P, Radiotherapy in palliative treatment of painful bone metastases. *Radial Oncol* 2009; 4: 213-24.

44. Pope WB, Sayre J, Perina A, Villalba JR, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. *Am J Neuroradiol* 2005; 26: 2466-74.

45. Hammond MA, Sawaya R, Shi W, Thall PF, Leedes NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. *J Neurooncol* 1996; 27: 65-73.